The Patent Finder

Terms ending in 2038

Hemanext Inc.

Every in-force patent on Hemanext Inc.'s record whose computed term ends in 2038, whoever holds it now. Soonest term end first, then patent number.
PatentTitleHolderStatusExpiresConfidence
US 10,898,517Methods and Treatment of Trauma Adverse Events with Oxygen Reduced Blood
In force
 · Medium confidence
Hemanext Inc.In forceMedium confidence
US 11,026,970Methods and Treatment of Trauma Adverse Events with Oxygen Reduced Blood
In force
 · High confidence
Hemanext Inc.In forceHigh confidence
US 11,026,971Methods and Treatment of Trauma Adverse Events with Oxygen Reduced Blood
In force
 · Low confidence
Hemanext Inc.In forceLow confidence
US 11,033,581Methods and Treatment of Trauma Adverse Events with Oxygen Reduced Blood
In force
 · Medium confidence
Hemanext Inc.In forceMedium confidence
US 11,052,110Methods and Treatment of Trauma Adverse Events with Oxygen Reduced Blood
In force
 · Low confidence
Hemanext Inc.In forceLow confidence
US 12,582,674Methods and Treatment of Trauma
In force
 · High confidence
Hemanext Inc.In forceHigh confidence
US 11,576,931Methods and Treatment of Trauma Adverse Events with Oxygen Reduced Blood
In force
 · Medium confidence
Hemanext Inc.In forceMedium confidence
7 of 7 patents shown. Soonest term end first, then patent number.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited